[FG] Papadopoulou Athina

Schoenholzer, K. et al. (2024) ‘Hemimacular Thinning Due to Lesions in the Lateral Geniculate Nucleus in 2 Patients With Neuroinflammatory Diseases’, Neurology Neuroimmunology & Neuroinflammation, 11(6). Available at: https://doi.org/10.1212/nxi.0000000000200297.

Gloor, Monika et al. (2024) ‘Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging’, European Radiology, 34, pp. 1680–1691. Available at: https://doi.org/10.1007/s00330-023-10173-6.

Kulsvehagen, L. et al. (2024) ‘Case report: Concurrent MOG antibody-associated disease and latent infections in two patients’, Frontiers in Immunology, 15. Available at: https://doi.org/10.3389/fimmu.2024.1455355.

Pakeerathan, T. et al. (2024) ‘Rapid differentiation of MOGAD and MS after a single optic neuritis’, Journal of Neurology [Preprint]. Available at: https://doi.org/10.1007/s00415-024-12666-w.

Papadopoulou, A. et al. (2024) ‘Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus’, Clinical Neurophysiology, 161, pp. 122–132. Available at: https://doi.org/10.1016/j.clinph.2024.02.020.

Zhu, Jie et al. (2024) ‘Reverse underwear sign as an indicator of alloknesis’, JDDG - Journal of the German Society of Dermatology, 22, pp. 574–575. Available at: https://doi.org/10.1111/ddg.15320.

Cagol A. et al. (2023) ‘Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.’, Journal of neurology, 270(4), pp. 2139–2148. Available at: https://doi.org/10.1007/s00415-022-11535-8.

Cerdá-Fuertes, Nuria et al. (2023) ‘Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150312.

Overeem, Lucas Hendrik et al. (2023) ‘Serum tau protein elevation in migraine: a cross-sectional case–control study’, Journal of Headache and Pain, 24. Available at: https://doi.org/10.1186/s10194-023-01663-5.

Friedli, C. et al. (2022) ‘Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022’, Clinical and Translational Neuroscience, 7(1), p. 2. Available at: https://doi.org/10.3390/ctn7010002.

Kenney R et al. (2022) ‘Normative Data and Conversion Equation for Spectral-Domain Optical Coherence Tomography in an International Healthy Control Cohort.’, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 42(4), pp. 442–453. Available at: https://doi.org/10.1097/wno.0000000000001717.

Kenney RC et al. (2022) ‘The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.’, Neurology, 99(11), pp. e1100–e1112. Available at: https://doi.org/10.1212/wnl.0000000000200883.

Stamatellos VP et al. (2022) ‘S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal.’, Multiple sclerosis and related disorders, 59, p. 103681. Available at: https://doi.org/10.1016/j.msard.2022.103681.

Tsagkas C et al. (2022) ‘Longitudinal changes of deep gray matter shape in multiple sclerosis.’, NeuroImage. Clinical, 35, p. 103137. Available at: https://doi.org/10.1016/j.nicl.2022.103137.

Wolleb, Julia et al. (2022) ‘Learn to Ignore: Domain Adaptation for Multi-site MRI Analysis’, in Medical Image Computing and Computer Assisted Intervention – MICCAI 2022. Singapore, September 18–22, 2022 (Medical Image Computing and Computer Assisted Intervention – MICCAI 2022), pp. 725–735. Available at: https://doi.org/10.1007/978-3-031-16449-1_69.

Anastasiou A et al. (2022) MRI with Contrast Agent Showing Arterial Wall Inflammation in Giant Cell Arteritis.

Anastasiou A et al. (2022) MRI with Contrast Agent Showing Arterial Wall Inflammation in Giant Cell Arteritis, p. 226.

Anastasiou A et al. (2022) MRI with Contrast Agent Showing Arterial Wall Inflammation in Giant Cell Arteritis. NA, p. 226.

Anastasiou A et al. (2022) MRI with Contrast Agent Showing Arterial Wall Inflammation in Giant Cell Arteritis. 4, p. 226.

Anastasiou A et al. (2022) MRI with Contrast Agent Showing Arterial Wall Inflammation in Giant Cell Arteritis. 4, p. 226.

Anastasiou A et al. (2022) MRI with Contrast Agent Showing Arterial Wall Inflammation in Giant Cell Arteritis. 4, p. 226.

Anastasiou A et al. (2022) MRI with Contrast Agent Showing Arterial Wall Inflammation in Giant Cell Arteritis. 4, p. 226.

Anastasiou A et al. (2022) MRI with Contrast Agent Showing Arterial Wall Inflammation in Giant Cell Arteritis. 2022 edn. 4, p. 226.

Tsagkas C et al. (2021) ‘Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.’, European journal of neurology, 28(12), pp. 4153–4166. Available at: https://doi.org/10.1111/ene.15098.

Lin TY et al. (2021) ‘Increased Serum Neurofilament Light and Thin Ganglion Cell-Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis.’, Neurology(R) neuroimmunology & neuroinflammation, 8(5). Available at: https://doi.org/10.1212/nxi.0000000000001051.

D’Souza M et al. (2021) ‘Standardization and digitization of clinical data in multiple sclerosis.’, Nature reviews. Neurology, 17(2), pp. 119–125. Available at: https://doi.org/10.1038/s41582-020-00448-7.

Papadopoulou A et al. (2021) ‘Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study.’, NeuroImage. Clinical, 30, p. 102608. Available at: https://doi.org/10.1016/j.nicl.2021.102608.

Tsagkas, Charidimos et al. (2021) ‘Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance’, Human brain mapping, 42(8), pp. 2399–2415. Available at: https://doi.org/10.1002/hbm.25375.

Magon S. et al. (2020) ‘Short timescale modulation of cortical and cerebellar activity in the early phase of motor sequence learning: an fMRI study’, Brain Imaging and Behavior, 14(6), pp. 2159–2175. Available at: https://doi.org/10.1007/s11682-019-00167-8.

Asseyer S et al. (2020) ‘Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders.’, Multiple sclerosis and related disorders, 46, p. 102579. Available at: https://doi.org/10.1016/j.msard.2020.102579.

Juenger V et al. (2020) ‘Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders.’, European radiology, 30(9), pp. 5048–5058. Available at: https://doi.org/10.1007/s00330-020-06859-w.

D’Souza M et al. (2020) ‘Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials’, Multiple Sclerosis Journal, 26(8), pp. 993–996. Available at: https://doi.org/10.1177/1352458519845108.

D’Souza M et al. (2020) ‘Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey.’, Multiple sclerosis and related disorders, 41, p. 102027. Available at: https://doi.org/10.1016/j.msard.2020.102027.

Zuber P et al. (2020) ‘Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results.’, Journal of neurology, 267(6), pp. 1744–1753. Available at: https://doi.org/10.1007/s00415-020-09768-6.

Magon S et al. (2020) ‘Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.’, Journal of neurology, 267(5), pp. 1536–1546. Available at: https://doi.org/10.1007/s00415-020-09740-4.

Derfuss T et al. (2020) ‘Advances in oral immunomodulating therapies in relapsing multiple sclerosis.’, The Lancet. Neurology, 19(4), pp. 336–347. Available at: https://doi.org/10.1016/s1474-4422(19)30391-6.

Kronlage C, Papadopoulou A and De Marchis GM (2020) ‘Isolated oculomotor palsy due to acute ischemic midbrain stroke’, Acta Neurologica Belgica. 28.04.2018, 120(2), pp. 479–481. Available at: https://doi.org/10.1007/s13760-018-0918-8.

Gkaniatsou T et al. (2020) ‘Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders.’, 120(1). Available at: https://doi.org/10.1007/s13760-019-01176-6.

Charidimos, Tsagkas et al. (2020) ‘Longitudinal patterns of cortical thinning in multiple sclerosis’, Human Brain Mapping, 41(8), pp. 2198–2215. Available at: https://doi.org/10.1002/hbm.24940.

Papadopoulou A et al. (2019) ‘Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway’, Neurology, 92(19), pp. E2240–E2249. Available at: https://doi.org/10.1212/wnl.0000000000007450.

Nolan-Kenney RC et al. (2019) ‘Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study’, Annals of Neurology. 10.04.2019, 85(5), pp. 618–629. Available at: https://doi.org/10.1002/ana.25462.

Papadopoulou, Athina et al. (2019) ‘Attack-related damage of Thalamic Nuclei in Neuromyelitis Optica Spectrum Disorders’, Journal of neurology, neurosurgery and psychiatry [Preprint]. Available at: https://doi.org/10.1136/jnnp-2018-320249.

Papadopoulou A et al. (2018) ‘[Optical Coherence Tomography in Disorders of the Central Nervous System].’, Klinische Monatsblatter fur Augenheilkunde, 235(11), pp. 1242–1258. Available at: https://doi.org/10.1055/a-0715-7961.

Magon S et al. (2018) ‘Cortical Thickness Alterations in Chronic Pain Disorder: An Exploratory MRI Study.’, Psychosomatic medicine, 80(7), pp. 592–598. Available at: https://doi.org/10.1097/psy.0000000000000605.

Papadopoulou A et al. (2018) Unilateral leg oedema due to spontaneous Achilles tendon rupture. 6, p. omy022. Available at: https://doi.org/10.1093/omcr/omy022.

Seifert CL et al. (2018) ‘Association of clinical headache features with stroke location: An MRI voxel-based symptom lesion mapping study.’, 38(2). Available at: https://doi.org/10.1177/0333102416686342.

Hanssen, H. et al. (2018) ‘Effects of different endurance exercise modalities on migraine days and cerebrovascular health in episodic migraineurs: A randomized controlled trial’, Scandinavian journal of medicine & science in sports, 28(3), pp. 1103–1112. Available at: https://doi.org/10.1111/sms.13023.

Papadopoulou A, Derfuss T and Sprenger T (2017) ‘Daclizumab for the treatment of multiple sclerosis.’, Neurodegenerative disease management, 7(5), pp. 279–297. Available at: https://doi.org/10.2217/nmt-2017-0023.

D’Souza M et al. (2017) ‘Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.’, Multiple sclerosis (Houndmills, Basingstoke, England), 23(4), pp. 597–603. Available at: https://doi.org/10.1177/1352458516657439.

Andermatt, Simon et al. (2017) ‘Tracking the Evolution of Cerebral Gadolinium-enhancing Lesions to Persistent T1 Black Holes in Multiple Sclerosis: Validation of a Semiautomated Pipeline’, Journal of Neuroimaging, 27(5), pp. 469–475. Available at: https://doi.org/10.1111/jon.12439.

Hanssen, Henner et al. (2017) ‘Superior Effects of High-Intensity Interval Training vs. Moderate Continuous Training on Arterial Stiffness in Episodic Migraine: A Randomized Controlled Trial’, Frontiers in Physiology, 8, p. 1086. Available at: https://doi.org/10.3389/fphys.2017.01086.

Papadopoulou A et al. (2015) ‘Decision for intravenous thrombolysis in a young patient with acute vertical gaze palsy.’, 115(3). Available at: https://doi.org/10.1007/s13760-014-0356-1.

Amann M et al. (2015) ‘Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis.’, Journal of neurology, 262(8), pp. 1909–17. Available at: https://doi.org/10.1007/s00415-015-7793-5.

Papadopoulou A, Kappos L and Sprenger T (2015) ‘Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.’, Expert opinion on drug safety, 14(5), pp. 749–59. Available at: https://doi.org/10.1517/14740338.2015.1014795.

Papadopoulou A et al. (2014) ‘MRI characteristics of periaqueductal lesions in multiple sclerosis.’, Multiple sclerosis and related disorders, 3(4), pp. 542–51. Available at: https://doi.org/10.1016/j.msard.2014.01.001.

Papadopoulou A, Ahlhelm FJ and Sprenger T (2014) ‘Intrathecal gadolinium for magnetic resonance myelography in spontaneous intracranial hypotension: valuable but may be risky--reply.’, 71(6). Available at: https://doi.org/10.1001/jamaneurol.2014.577.

Papadopoulou, A. et al. (2014) ‘Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis’, Multiple Sclerosis Journal, 20(3), pp. 322–30. Available at: https://doi.org/10.1177/1352458513495583.

Yaldizli, O. et al. (2014) ‘The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients’, Multiple Sclerosis Journal, 20(3), pp. 356–364. Available at: https://doi.org/10.1177/1352458513496880.

Papadopoulou A et al. (2013) ‘Detection of cerebrospinal fluid leaks by intrathecal contrast-enhanced magnetic resonance myelography.’, JAMA neurology, 70(12), pp. 1576–7. Available at: https://doi.org/10.1001/jamaneurol.2013.744.

Papadopoulou A et al. (2013) ‘Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis’, Multiple Sclerosis Journal, 19(10), pp. 1290–1296. Available at: https://doi.org/10.1177/1352458513475490.

Papadopoulou A, Kappos L and Sprenger T (2012) ‘Teriflunomide for oral therapy in multiple sclerosis.’, Expert review of clinical pharmacology, 5(6), pp. 617–28. Available at: https://doi.org/10.1586/ecp.12.56.

Papadopoulou A et al. (2012) ‘Evolution of MS lesions to black holes under DNA vaccine treatment.’, Journal of neurology. 06.01.2012, 259(7), pp. 1375–82. Available at: https://doi.org/10.1007/s00415-011-6361-x.

Yaldizli Ö et al. (2011) ‘Fatigue and progression of corpus callosum atrophy in multiple sclerosis.’, Journal of neurology. 19.05.2011, 258(12), pp. 2199–205. Available at: https://doi.org/10.1007/s00415-011-6091-0.

Radue EW et al. (2010) ‘Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.’, Journal of the neurological sciences. 16.03.2010, 292(1-2), pp. 28–35. Available at: https://doi.org/10.1016/j.jns.2010.02.012.

Papadopoulou, Athina et al. (2010) ‘Dimethyl fumarate for multiple sclerosis’, Expert opinion on investigational drugs, 19(12), pp. 1603–12. Available at: https://doi.org/10.1517/13543784.2010.534778.